Articles with public access mandates - Salvatore SienaLearn more
Not available anywhere: 9
Integrating liquid biopsies into the management of cancer
G Siravegna, S Marsoni, S Siena, A Bardelli
Nature reviews Clinical oncology 14 (9), 531-548, 2017
Mandates: Government of Italy
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ...
The Lancet Oncology 22 (6), 779-789, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
Precision oncology in metastatic colorectal cancer—from biology to medicine
F Di Nicolantonio, PP Vitiello, S Marsoni, S Siena, J Tabernero, ...
Nature reviews Clinical oncology 18 (8), 506-525, 2021
Mandates: Cancer Research UK, European Commission, Government of Spain, Government of …
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis
F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ...
Clinical colorectal cancer 16 (3), e153-e163, 2017
Mandates: European Commission
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies
G Mauri, EG Pizzutilo, A Amatu, K Bencardino, L Palmeri, EF Bonazzina, ...
Cancer treatment reviews 73, 41-53, 2019
Mandates: European Commission
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression
RJP Bonnal, G Rossetti, E Lugli, M De Simone, P Gruarin, J Brummelman, ...
Nature immunology 22 (6), 735-745, 2021
Mandates: Cancer Research UK, Government of Italy, AIRC Foundation for Cancer Research …
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
G Mauri, V Gori, E Bonazzina, A Amatu, F Tosi, K Bencardino, L Ruggieri, ...
Cancer Treatment Reviews 91, 102112, 2020
Mandates: Cancer Research UK, European Commission, Government of Italy, AIRC …
Human epidermal growth factor receptor 2 as a molecular biomarker for metastatic colorectal cancer
A Sartore-Bianchi, S Marsoni, S Siena
JAMA oncology 4 (1), 19-20, 2018
Mandates: European Commission, Government of Italy
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
C Vaghi, G Mauri, AG Agostara, G Patelli, EG Pizzutilo, Y Nakamura, ...
Cancer Treatment Reviews 112, 102488, 2023
Mandates: AIRC Foundation for Cancer Research in Italy
Available somewhere: 119
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
Mandates: US National Institutes of Health, Wellcome Trust, Government of Italy
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
Mandates: US National Institutes of Health
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
MS Brose, CM Nutting, B Jarzab, R Elisei, S Siena, L Bastholt, ...
The Lancet 384 (9940), 319-328, 2014
Mandates: US National Institutes of Health
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
Mandates: US National Institutes of Health, Alex's Lemonade Stand
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
Mandates: US National Institutes of Health, Government of Spain, Government of Italy
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
Mandates: Research Foundation (Flanders)
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
Mandates: US National Institutes of Health
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
Mandates: US National Institutes of Health
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials
A Lipton, K Fizazi, AT Stopeck, DH Henry, JE Brown, DA Yardley, ...
European journal of cancer 48 (16), 3082-3092, 2012
Mandates: Cancer Research UK
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ...
Nature 552 (7683), 116-120, 2017
Mandates: Swiss National Science Foundation, Government of Italy
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya, JHM Schellens, T Yoshino, JC Bendell, ...
Cancer discovery 8 (4), 428-443, 2018
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Publication and funding information is determined automatically by a computer program